Background: Phase II data suggested that guselkumab, an anti-interleukin-23 monoclonal antibody, was efficacious in psoriasis.
Psoriasis is a chronic immune-mediated inflammatory disease. Although therapeutic options have progressively expanded for moderate to severe psoriasis, new unmet needs have emerged.
1,2 Standards for treatment goals have escalated; patients often desire complete skin clearance 3, 4 and improved long-term efficacy. 5, 6 In addition, as new therapeutic options become available, more information is needed about interruption of and transition between treatments.
Recent studies of biologics for psoriasis treatment demonstrated substantial efficacy by selectively blocking the interleukin (IL)-23 or IL-17 pathways, both central to psoriasis pathogenesis. [7] [8] [9] [10] [11] [12] [13] [14] Current findings show that selective inhibition of IL-23 alone results in clinical response and molecular improvements in the skin. 7, 9, 12, 13 Guselkumab (CNTO 1959; Janssen Research & Development, LLC, Spring House, PA) is a fully human IgG1 lambda monoclonal antibody that binds IL-23 and blocks binding and signaling through its receptor. High levels of efficacy were suggested in phase I 13 and phase II 7 studies. To confirm the therapeutic potential of guselkumab, the phase III VOYAGE 1 15 and VOYAGE 2 studies assessed the efficacy and safety of guselkumab versus placebo and adalimumab. VOYAGE 1 assessed continuous 1-year treatment, and VOYAGE 2 evaluated the efficacy and safety of interrupted treatment, as treatment gaps frequently occur in clinical practice. [16] [17] [18] [19] In addition, VOYAGE 2 assessed the transition from adalimumab to guselkumab, providing clinically relevant information about patients who switch biologics.
METHODS Patients
Adults (aged $18 years) with moderate to severe plaque-type psoriasis were eligible. Major inclusion/exclusion criteria are summarized in VOYAGE 1 (NCT02207231). 15 The study protocol was approved by investigational review boards at each site, and written informed consent was provided by all patients.
Study design
VOYAGE 2 was a phase III, multicenter, randomized, double-blind, placebo-and adalimumab comparatorecontrolled study (NCT02207244) conducted in 115 global sites from November 2014 to May 2016. The study consisted of a placebo-controlled period (weeks 0-16), an active comparatorecontrolled period (weeks 0-28),
CAPSULE SUMMARY d
Guselkumab effectively treated moderate to severe psoriasis in the phase II X-PLORE study. and a randomized withdrawal and retreatment period (weeks . Study results through week 48 are presented here. Patients were randomized 2:1:1 using a permuted block method at baseline to guselkumab 100 mg at weeks 0, 4, 12, and 20; placebo at weeks 0, 4, and 12, then guselkumab at weeks 16 and 20; or adalimumab 80 mg at week 0, 40 mg at week 1, and every 2 weeks thereafter through week 23 (Fig 1) . Central randomization occurred using an interactive webbased response system (Perceptive Informatics, East Windsor, NJ).
At week 28, guselkumab-treated patients achieving 90% or greater improvement in Psoriasis Area and Severity Index (PASI) score from baseline (PASI 90) (responders) were rerandomized in a 1:1 ratio to guselkumab or placebo. Upon loss of 50% or more of week-28 PASI response, patients were retreated with guselkumab, another dose 4 weeks later, then every 8 weeks (q8w) thereafter. Guselkumab nonresponders continued guselkumab treatment. Placebo/guselkumab nonresponders at week 28 continued guselkumab q8w, whereas responders received placebo q8w beginning at week 28. Upon loss of 50% or more of week-28 PASI response, patients were retreated with guselkumab, another dose 4 weeks later, then q8w thereafter. Adalimumab nonresponders initiated guselkumab at week 28, another dose 4 weeks later, then q8w thereafter. Adalimumab responders received placebo and upon loss of 50% or more of week-28 PASI response, initiated guselkumab, another dose 4 weeks later, then q8w thereafter (Fig 1) . To maintain the blind, both guselkumab and adalimumab placebos were administered as necessary.
Efficacy and safety assessments
Efficacy was assessed through week 24 and safety through week 28. Key efficacy, including general and regional psoriasis, patient-reported outcomes, and safety assessments are discussed in detail in the VOYAGE 1 study. 15 In addition, the Medical Outcomes Study 36-Item Short Form 20 was evaluated in this study.
Study end points
The coprimary end points were the proportions of patients achieving an Investigator Global Assessment (IGA) score of cleared/minimal (0/1) (IGA 0/1) at week 16 and the proportion of patients achieving a PASI 90 response at week 16, comparing the guselkumab and placebo groups. Major secondary end points are listed in Table I . Regional psoriasis end points evaluating the scalp, fingernails, and hand/feet were described in detail elsewhere. 15 
Statistical analysis
All randomized patients were included in the primary analysis and some secondary efficacy analyses according to their assigned treatment group. To assess maintenance dosing versus treatment withdrawal for the major secondary end points, all patients who underwent the second randomization and had PASI evaluations after week 28 were included.
The coprimary end points and binary major secondary end points were analyzed using a 2-sided Cochran-Mantel-Haenszel x 2 statistical test (a = 0.05) stratified by investigator site. Continuous response parameters were compared using an analysis of variance model with site as a covariate. For the time to loss of PASI 90 response, the log-rank test stratified by site was used.
Patients who discontinued treatment due to lack of efficacy or an adverse event [AE] of worsening of psoriasis, or started a protocol-prohibited medication/therapy to improve psoriasis were considered treatment failures. Patients meeting treatment failure criteria before week 16 and patients not returning for week-16 evaluation were considered nonresponders for the week-16 primary end point. For patients randomized to placebo, only those crossing over to guselkumab at or after week 16 were included in efficacy analyses after week 16.
To control the overall type 1 error rate, the primary and major secondary analyses were tested in a fixed sequence, with the first major secondary end point tested only if the coprimary end points were met, and the subsequent end point(s) tested 
RESULTS

Patient disposition and baseline demographic characteristics
In total, 1279 patients were screened and 992 were randomized 2:1:1 to receive guselkumab (n = 496), placebo (n = 248), or adalimumab (n = 248) (Fig 2) . Overall, 9.7% (96 of 992) of patients discontinued the study agent through week 48 (guselkumab 7.9%; placebo 11.7%; adalimumab 11.3%) (Fig 2) . Baseline demographics and disease characteristics were generally comparable among groups (Table II) .
Efficacy
Guselkumab was superior to both placebo and adalimumab with respect to the coprimary end points and all major secondary end points (P \.001).
Placebo-controlled period (weeks 0-16). At week 16, significantly greater proportions of patients receiving guselkumab achieved IGA 0/1 compared with those receiving placebo (84.1% vs 8.5%; P \ .001) and achieved a PASI 90 response (70.0% vs 2.4%; P \.001) (Table III) (coprimary end points). J AM ACAD DERMATOL VOLUME 76, NUMBER 3 Significantly higher percent improvement in PASI score was observed as early as week 2 in guselkumab versus placebo groups (P \ .001). In addition, at week 16, significantly higher proportions of patients receiving guselkumab achieved 75% or greater (PASI 75) and 100% improvement in PASI score from baseline (PASI 100) responses compared with those receiving placebo (Table III) . Patients treated with guselkumab achieved greater improvement in all regional psoriasis outcome assessments compared with placebo at week 16 including: scalp-specific IGA, fingernail Physician Global Assessment, Nail Psoriasis Severity Index, and Physician Global Assessment of hands and/or feet (Table III) . Similar to VOYAGE 1, 15 guselkumab was superior to placebo at week 16 in all patient-reported outcomes including Dermatology Life Quality Index (DLQI), 21 Psoriasis Symptoms and Signs Diary (PSSD), 22, 23 and Medical Outcomes Study 36-Item Short Form 20 (Table III) .
Active-comparator period (weeks 0-24). Significantly greater proportions of patients receiving guselkumab versus adalimumab achieved IGA 0/1, PASI 90, and PASI 75 responses at week 16 (Table III) . At week 24, significantly higher response rates were maintained in the guselkumab versus adalimumab groups for IGA 0 (51.8% vs 31.5%), IGA 0/1 (83.5% vs 64.9%), PASI 90 (75.2% vs 54.8%), and DLQI, Dermatology Life Quality Index; IGA 0, Investigator Global Assessment score of 0 (cleared); IGA 0/1, Investigator Global Assessment score of 0 (cleared) or 1 (minimal); PASI 75, 75% or greater improvement from baseline in Psoriasis Area and Severity Index score; PASI 90, 90% or greater improvement from baseline in Psoriasis Area and Severity Index score; PSSD, Psoriasis Symptoms and Signs Diary; ss-IGA 0/1, scalp-specific Investigator Global Assessment score of 0 (absence of disease) or 1 (very mild disease). *To control the overall type 1 error rate, the primary analysis and major secondary analyses were tested using a fixed sequence method. Specifically, the first major secondary end point was tested only if the coprimary end points were positive, and subsequent end points were tested only if the preceding end point was positive. y Tested for noninferiority of the guselkumab group compared with the adalimumab group. z Tested for superiority of the guselkumab group compared with the adalimumab group.
x Included only randomized patients with baseline ss-IGA score $2 and who achieved $2-grade improvement. k Included only randomized patients with PSSD symptom score $1 at baseline.
PASI 100 (44.2% vs 26.6%) (Fig 3 and Table III ). Consistent with VOYAGE 1, 15 greater improvements in regional psoriasis disease scores were observed at week 24 in patients receiving guselkumab versus adalimumab, with the exception of fingernail Physician Global Assessment score 0/1 and percent improvement in Nail Psoriasis Severity Index score, which were comparable (Table III) . At week 24, the proportions of patients achieving DLQI score 0/1, PSSD symptom score of 0, PSSD sign score of 0, and mean changes in the PSSD symptom and sign scores were significantly greater in the guselkumab group than in the adalimumab group (P \.001) (Table III) .
Randomized withdrawal and retreatment period (weeks . PASI 90 responses were better maintained in guselkumab week-28 responders continuing guselkumab (maintenance group) versus responders rerandomized to placebo (withdrawal group). The median time to loss of PASI 90 response was 15.2 weeks (23 weeks after last guselkumab dose) for patients randomized to the withdrawal group. Among patients withdrawn from guselkumab at week 28, PASI 90 response rates began to diverge from the maintenance group at week 32. Through week 48, 88.6% of patients in the maintenance group sustained a PASI 90 response versus 36.8% of those in the withdrawal group. At week 48, clinical responses (IGA, PASI) were significantly greater in the maintenance than in the withdrawal group (Fig 4) (P \.001). Improvements in DLQI and PSSD symptom or sign scores from baseline were also significantly greater at week 48 in the maintenance versus withdrawal groups (P \ .001). Through week 48, a small number of patients (n = 16) were retreated with guselkumab.
Switching adalimumab nonresponders to guselkumab. Overall, 112 adalimumab nonresponders initiated guselkumab at week 28 (5 weeks after the last adalimumab dose). In these patients, PASI 90 and PASI 100 response rates (relative to baseline) increased after switching, reaching 66.1% and 28.6%, respectively, at week 48.
Safety
Placebo-controlled period (weeks 0-16). The proportions of patients with 1 or more AEs, AEs leading to discontinuation, and SAEs were comparable between the guselkumab and placebo groups (Table IV) . The most commonly reported events were nasopharyngitis, headache, and upper (Table IV) . A higher proportion of adalimumab patients had injection site reactions (ISR) (6.9% vs 2.6%) and injections resulting in ISRs (1.5% vs 0.9%) versus guselkumab patients. Most ISRs were mild. Active-comparator period (weeks 0-28). The types of AEs were similar to those reported in the placebo-controlled period (Table IV) . The proportions of patients with 1 or more AE, AEs leading to discontinuation, and SAEs were comparable between the guselkumab and adalimumab groups. Infections and infections requiring treatment were also comparable between guselkumab and adalimumab groups. Three serious infections each were reported in the guselkumab (bronchitis, erysipelas, and soft-tissue infection) and adalimumab (2 cases of tuberculosis [1 disseminated], and 1 injection-site abscess) groups. One malignancy (prostate cancer) and 2 NMSCs (1 squamous cell carcinoma in the guselkumab group and 1 basal cell carcinoma in the placebo/guselkumab group) were reported. Two MACE (1 myocardial infarction each in the guselkumab and adalimumab groups) were reported (Table IV) .
Randomized withdrawal and retreatment period (weeks Rates of abnormal laboratory results were low and comparable between treatment groups through week 48. Antibodies to guselkumab were detected in 57 of 869 patients (6.6%) through week 48; titers were generally low (88% #1:160). No apparent associations were observed between antibody development and decreased efficacy or ISR development (data not shown).
DISCUSSION
VOYAGE 2 confirms the results of VOYAGE 1, 15 demonstrating that guselkumab is highly effective in treating a broad moderate to severe psoriasis population. Guselkumab was superior to placebo at the week-16 coprimary end points (IGA 0/1 and PASI 90). Guselkumab was also superior to adalimumab at the week-16 end points (IGA 0/1, PASI 75/PASI 90), and at week 24 (IGA 0, PASI 90 and PASI 100). Guselkumab successfully treated difficult regional psoriasis, including scalp, nails, and hands/feet. Investigator-assessed improvements were mirrored by improvements in the patient-reported outcomes evaluated in VOYAGE 1 15 (DLQI and PSSD). In addition, significant improvements in health-related quality of life (Medical Outcomes Study 36-Item Short Form) were reported in VOYAGE 2. The combined robust and comprehensive results from VOYAGE 1 15 and VOYAGE 2 demonstrated superiority to both placebo and adalimumab. Consistent with findings of other psoriasis biologics, [24] [25] [26] [27] VOYAGE 2 demonstrated that maintenance was superior to interrupted therapy, and blockade of IL-23 did not reverse the underlying mechanism of psoriasis. Unlike VOYAGE 1, 15 in which patients continued treatment for 48 weeks, in VOYAGE 2, PASI 90 responders were randomized at week 28 to continue guselkumab or receive placebo. Guselkumab-treated patients maintained response, including PASI 90, PASI 100, and IGA 0, whereas psoriasis slowly recurred and health-related quality of life was reduced in patients receiving placebo. The median time to loss of PASI 90 response for withdrawal patients (15.2 weeks) is relevant because discontinuation rates are significant with psoriasis biologics use through 1 year (often 50%). [17] [18] [19] Guselkumab was effective in treating adalimumab nonresponders (not achieving PASI 90). Patients were classified as responders/nonresponders at week 28, 5 weeks after the last adalimumab injection. After 20 weeks of guselkumab treatment, two thirds of the 112 adalimumab nonresponders who switched to guselkumab achieved PASI 90 (relative to baseline). Determining the rate at which patients who have had suboptimal responses achieve treatment goals could have a significant impact on treatment decisions for those seeking greater clearance, as more effective psoriasis therapies emerge. [17] [18] [19] Although the mechanism of action for the broader efficacy of guselkumab is unknown, in psoriasis, tumor necrosis factor-a (released from
CD163
1 macrophages/CD11c 1 dendritic cells) 28 and IL-17A (released from neutrophils, mast cells, and T-helper 17 cells) 29 are effector cytokines primarily acting on keratinocytes. IL-23 could be viewed as the overarching master cytokine for psoriasis because it drives the activation of T cells 30 and induces IL-17 production. Moreover, IL-23 induces T-helper 17 and other innate cells to produce IL-22, another cytokine implicated in psoriasis pathogenesis. 31 Therefore, targeting the IL-23 pathway with an antibody such as guselkumab can provide higher efficacy and durable responses. The safety profile of guselkumab in this study was consistent with VOYAGE 1. 15 The rates and types of AEs, SAEs, and abnormal laboratory results were generally comparable with placebo though week 16 and adalimumab through week 28. Through week 48, rates of serious infections, malignancies, and MACE were low across groups. Overall, there were 2 cases of tuberculosis, both in patients taking adalimumab. There were 5 malignancies in the guselkumab-treated patients, 4 of which were NMSCs (2 basal cell carcinoma and 2 squamous cell carcinoma). ISRs occurred more frequently in patients receiving adalimumab. Although the safety profile of guselkumab is favorable, the size and duration of the study was inadequate to detect rare events.
There are several other limitations of VOYAGE 2. Although comparison of guselkumab with adalimumab in VOYAGE 2 was limited to 24 weeks, VOYAGE 1 15 extended the comparison with adalimumab through 48 weeks. More importantly, at week 48, few VOYAGE 2 patients withdrawn from active Values are n (%) unless otherwise indicated. AE, Adverse event; MACE, major adverse cardiovascular event; NMSC, nonmelanoma skin cancer; PASI, Psoriasis Area and Severity Index; SAE, serious adverse event. *Includes guselkumab wk-28 90% or greater improvement in PASI score from baseline (PASI 90) responders rerandomized at wk 28 to continue guselkumab 100 mg every 8 wk.
y Includes guselkumab wk-28 PASI 90 responders rerandomized at wk 28 to placebo (withdrawal), then retreated with guselkumab 100 mg every 8 wk after 50% or more loss of wk-28 PASI 90
response.
z Occurred in at least 5% of patients in any treatment group.
x Includes malignancies other than NMSC (prostate cancer, n = 1).
k Includes basal cell and squamous cell carcinomas. { Includes sudden cardiac death, myocardial infarction, and stroke.
therapy lost adequate response to assess the efficacy and safety of retreatment. However, these numbers will be evaluated at a later study time point.
In conclusion, VOYAGE 2 confirms the results of VOYAGE 1 15 that guselkumab demonstrated superior efficacy to adalimumab and comparable safety when administered in a convenient dosage regimen of a single 100-mg injection at weeks 0 and 4, and q8w. These results suggest that guselkumab may be an important addition to psoriasis treatment alternatives. In addition, VOYAGE 2 provides important data on the need for continuing therapy with guselkumab to maintain the highest level of response, and successful transition from adalimumab to guselkumab.
